Loading
If this is the first time anyone has visited this substance, we may be fetching live data from TGA Product Information, PBS, and state framework sources — that can take up to a minute. Cached substances load in a second or two.
Curated subset. The full adverse-effect list is in the TGA Product Information; click any citation above to open it.
“Irinotecan hydrochloride is an antineoplastic agent of the topoisomerase I inhibitor class.”
“After intravenous infusion of irinotecan hydrochloride in humans with various cancers, irinotecan hydrochloride plasma concentrations decline in a multiexponential manner, with a mean terminal elimination half-life of about 6 to 12 hours. The mean terminal elimination half-life of the active metabolite SN-38 is about 10 to 20 hours.”
Working under the parallel aged-care framework? Aged-care equivalent →
“Irinotecan hydrochloride is oxidised by cytochrome P450 isozyme 3A4 (CYP3A4) to yield two relatively inactive metabolites, APC (7-ethyl-l0-[4-N-(5-aminopentanoic acid)-l-piperidino]- carbonyloxycamptothecin) and the minor metabolite, NPC (7-ethyl-l0-(4-amino-1- piperidino)carbonyloxycamptothecin.”